Specializing in pharmaceuticals, the company has developed FDA-approved treatments for rare diseases, including one orphan drug designation for medullary thyroid gland carcinoma.
1
Orphan Designations
0 approved, 1 designated
8
FDA Approvals
Latest: ELCYS (2019)
0
Active Trials
1
Rare Diseases
across 2 areas
0
News (30d)
Quiet
Exela Pharma Sciences, LLC is a company with 1 orphan drug designation across 1 rare disease, including 8 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| medullary thyroid gland carcinoma | pentagastrin | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio